{
 "id": "asthma",
 "name": "Asthma",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "respiratory",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 1,
  "closed": 3
 },
 "funds": [
  {
   "fund": "Asthma",
   "organization": "Accessia Health",
   "status": "waitlist",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The program page lists the program as At Capacity, Waitlist Open. It shows no date.",
   "readOn": "2026-11-10",
   "source": "https://accessiahealth.org/program/asthma/"
  },
  {
   "fund": "Asthma",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Asthma",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 3500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "fund": "Asthma health equity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 3500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "OMALIZUMAB",
   "pages": [
    {
     "brand": "Xolair",
     "url": "https://omnirx.org/negotiated-drugs/xolair"
    }
   ],
   "labelSentence": "Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%227f6a2191-adfb-48b9-9bfa-0d9920479f0d%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Asthma Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/asthma-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Genentech Patient Foundation",
     "url": "https://omnirx.org/assistance/genentech-access-solutions",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Our Participating Medicines",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Benralizumab",
   "pages": [
    {
     "brand": "Fasenra",
     "url": "https://omnirx.org/medicines/fasenra"
    }
   ],
   "labelSentence": "... add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22da6aca1a-19ed-44a4-abb7-696c7d58b784%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Asthma Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/asthma-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Dupilumab",
   "pages": [
    {
     "brand": "Dupixent",
     "url": "https://omnirx.org/medicines/dupixent"
    }
   ],
   "labelSentence": "Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22595f437d-2729-40bb-9c62-c8ece1f82780%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Dupixent MyWay",
     "url": "https://omnirx.org/assistance/dupixent-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Asthma Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/asthma-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Fluticasone Furoate",
   "pages": [
    {
     "brand": "Arnuity Ellipta",
     "url": "https://omnirx.org/medicines/arnuity-ellipta"
    }
   ],
   "labelSentence": "ARNUITY ELLIPTA is indicated for the maintenance treatment of asthma in adult and pediatric patients aged 5 years and older.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2250f193ee-1691-486d-9370-a664df63695c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "GSK Patient Assistance Program (GSK ViiV Healthcare Patient Access Programs Foundation)",
     "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "List of eligible products (GSK prescription medicines)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Mepolizumab",
   "pages": [
    {
     "brand": "Nucala",
     "url": "https://omnirx.org/medicines/nucala"
    }
   ],
   "labelSentence": "Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22fefb887c-e4ac-431e-8893-e9d1a5a63fea%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Asthma Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/asthma-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "GSK Patient Assistance Program (GSK ViiV Healthcare Patient Access Programs Foundation)",
     "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "List of eligible products (GSK prescription medicines)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tezepelumab-Ekko",
   "pages": [
    {
     "brand": "Tezspire",
     "url": "https://omnirx.org/medicines/tezspire"
    }
   ],
   "labelSentence": "... for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2260f0aa03-ad25-4d48-80ce-7fcfa76f325f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Amgen Safety Net Foundation",
     "url": "https://www.amgensafetynetfoundation.com/eligibility.html",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Eligibility page medication selector (tile titles)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Albuterol Sulfate",
   "pages": [
    {
     "brand": "Albuterol Sulfate HFA",
     "url": "https://omnirx.org/medicines/albuterol-sulfate-hfa"
    },
    {
     "brand": "Ventolin HFA",
     "url": "https://omnirx.org/medicines/ventolin-hfa"
    }
   ],
   "labelSentence": "Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221d6be2b8-c670-b783-e063-6294a90ae503%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Budesonide/Formoterol Fumarate",
   "pages": [],
   "labelSentence": "Treatment of asthma in patients 6 years of age and older.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220ce4cd21-ac96-4b39-9e1c-49f86c87fa1a%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Corticotropin",
   "pages": [
    {
     "brand": "Acthar",
     "url": "https://omnirx.org/medicines/acthar"
    }
   ],
   "labelSentence": "Bronchial asthma;",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22110a17aa-6ed9-4458-8e67-1a742ce448e4%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Fluticasone Propionate",
   "pages": [],
   "labelSentence": "FLOVENT DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22038e6c40-9421-40ef-874b-8f4d7110a74a%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}